The authors described AZD7442, a combination of two mAbs, AZD8895 and AZD1061, that simultaneously bound to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2.
[Science Translational Medicine]
Sorry, but the selected Zotpress account can't be found.
